Drug intelligence / Profile preview

SANA-01 ADC

Development stage: Preclinical
Lead developer: Sanavia Oncology
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

SANA-01 ADC is a preclinical-stage antibody-drug conjugate (ADC) being developed by Sanavia Oncology for the treatment of various solid tumors. The therapeutic candidate specifically targets Mucin-1 (MUC-1), a cell surface glycoprotein that is highly expressed and aberrantly glycosylated in several malignancies, including lung, breast, ovarian, and gastrointestinal cancers. By utilizing the ADC modality, SANA-01 is designed to selectively deliver a potent cytotoxic agent to MUC-1-positive cancer cells, thereby enhancing anti-tumor activity while reducing off-target effects associated with systemic chemotherapy.

Other names: SANA-01SANA01SANA 01

Targets

MUC1 (Mucin-1 Antigen)

Beyond the preview

Go deeper on SANA-01 ADC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SANA-01 ADC.

Explore the full profile